Background Since licensure in 2006, rotavirus vaccines have been introduced in more than
100 countries. The efficacy of rotavirus vaccines is variable in settings with different child …

Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed for global use in
2006. A systematic review of 48 peer-reviewed articles with postlicensure data from 24 …

Background: The test-negative design is an increasingly popular approach for estimating
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …

Background: Rotavirus is the leading cause of vaccine-preventable diarrhea among children
under 5 globally. Rotavirus vaccination has been shown to prevent severe rotavirus …

Background Acute gastroenteritis (AGE) is a major cause of morbidity and mortality in
children aged less than 5 years in low-and middle-income countries where limited access to …

Importance Rotavirus vaccines have been introduced worldwide, and the clinical
association of different rotavirus vaccines with reduction in rotavirus gastroenteritis (RVGE) …

Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following
the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe …

Background Rotavirus was the leading cause of childhood diarrhoea-related
hospitalisations and death before the introduction of rotavirus vaccines. Methods We …

Background Rotavirus was the leading cause of acute gastroenteritis (AGE) in infants and
young children prior to the introduction of routine vaccination. Since 2006 there have been …

Abstract Background. The Republic of Moldova was the first low-to middle-income country in
the World Health Organization European Region to introduce rotavirus vaccine (July 2012) …